The 2021 DORIS Definition Of Remission In Systemic Lupus Erythematosus – Final Recommendations from an International Task Force

Ian Bruce, et al.

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To achieve consensus on a definition of remission in systemic lupus erythematosus (DORIS).

Background: Remission is the stated goal for both patient and care-giver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a frame-work for such a definition, without reaching a final recommendation.

Methods: Several systematic literature reviews were performed and specific research questions examined in suitably chosen datasets. The findings were discussed, reformulated as recommendations, and voted upon.

Results: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical SLEDAI = 0, evaluator’s global assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics.

Conclusion: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
Original languageEnglish
JournalLupus Science and Medicine
Publication statusAccepted/In press - 4 Nov 2021

Fingerprint

Dive into the research topics of 'The 2021 DORIS Definition Of Remission In Systemic Lupus Erythematosus – Final Recommendations from an International Task Force'. Together they form a unique fingerprint.

Cite this